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Chapter 18
Hypoxia Imaging with 18F-FMISO PET
for Brain Tumors
Kenji Hirata, Kentaro Kobayashi, and Nagara Tamaki
Abstract Tumor hypoxia is an important object for imaging because hypoxia is
associated with tumor aggressiveness and resistance to radiation therapy. Here, 18F-
fluoromisonidazole (FMISO) has been used for many years as the most commonly
employed hypoxia imaging tracer. Unlike F-18 fluorodeoxyglucose (FDG), FMISO
does not accumulate in normal brain tissue making it able to provide images of
hypoxic brain tumors with high contrast. Clinical evidence has suggested that
FMISO PET can predict patient prognosis and treatment response. Among gliomas
of various grades (WHO 2007), it has been known that grade IV glioblastoma
resides under severe hypoxia and is a cause of development of necrosis in the
tumor. For this study we tested whether FMISO can distinguish the oxygen condi-
tion of glioblastomas and lower-grade gliomas. Twenty-three glioma patients
underwent FMISO PET for the study. All the glioblastoma patients (N¼ 14)
showed high FMISO uptakes in the tumor, whereas none of the other patients
(i.e., gliomas of grade III or lower, N¼ 9) did, demonstrated by both qualitative
and quantitative assessments. The data suggest that FMISO PET may be a useful
tool to distinguish glioblastomas from lower-grade gliomas. Our results, however,
were slightly different from previous investigations reporting that some lower-
grade gliomas (e.g., grade III) showed positive FMISO uptake. Many of these
acquired the FMISO PET images 2 h after the FMISO injection, while for the
study here we waited 4 h to be able to collect hypoxia-specific signals rather than
perfusion signals as FMISO clearance from plasma is slow due to its lipophilic
nature. No optimum uptake time for FMISO has been established, and we directly
compared the 2-h vs. the 4-h images with the same patients (N¼ 17). At 2 h, the
gray matter had significantly higher standardized uptake value (SUV) than the
white matter, possibly due to different degrees of perfusion but not due to hypoxia.
At 4 h, there were no differences between gray and white matter without any
significant increase in the noise level measured by the coefficient of variation
between the 2-h and the 4-h images. At 2 h, 6/8 (75 %) of glioblastoma patients
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showed higher uptakes in the tumor than in the surrounding brain tissue, whereas at
4 h this was the case for 8/8 (100 %). In addition, at 2 h, 3/4 (75 %) of patients with
lower-grade gliomas showed moderate uptakes, while at 4 h none did (0/4 or 0 %).
These data indicate that 4-h images are better than 2-h images for the purpose of glioma
grading. In conclusion, we evaluated the diagnostic performance of FMISO PET for
gliomas and suggest that FMISO PET may be able to assist in the diagnosis of
glioblastomas when PET images are acquired at 4 h post injection.
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18.1 Introduction
This review article summarizes our recent studies with 18F-fluoromisonidazole
(FMISO) positron emission tomography (PET) applied to brain tumors [1, 2]. A
variety of tumors which can be divided into two categories develop in the brain:
primary brain tumors that originate from the brain tissue and metastatic brain tumors
that originate from malignant tumors in other organs. Gliomas account for 60 % of
primary brain tumors. Gliomas comprise a range of tumors, from benign to malignant,
that are derived from glial cells such as astrocytes, oligodendrocytes, and ependymal
cells. Among gliomas, the glioblastoma is the most aggressive astrocytic tumor.
Glioblastomas are categorized as grade IV in theWHO classification [3]. The standard
treatment for glioblastomas is surgery followed by radiotherapy and chemotherapy [4].
With state-of-the-art multidisciplinary therapy, the 1-year survival rate of glioblas-
toma patients is reported to be 56 %, which is significantly poorer than with grade III
(78 %) or less malignant gliomas [5]. A pathological diagnosis of surgical specimens
by biopsy or resection is necessary to establish the diagnosis for glioblastomas [6], but
brain surgery involving eloquent regions can exacerbate the prognosis by causing
neurological morbidity and should be avoided if possible [7]. Patients with impaired
performance status or elderly patients especially would benefit from nonsurgical
methods of establishing the diagnosis, substituting surgical tissue sampling.
The basic in vivo imaging modality for brain tumors is magnetic resonance
(MR) imaging. Intratumoral characteristics and tumor expansion states are shown
accurately with MR imaging. The use of PET with 18F-fluorodeoxyglucose (FDG)
is a well-established method for many different types of tumors in the body,
including lung cancer, head and neck cancers, and others. FDG PET also plays
important roles in the diagnosis of glioblastomas. The diagnosis of a glioblastoma is
generally suggested if there is a ringlike enhancement by gadolinium onMR images
or an intense uptake of FDG [6, 8–15]. However, there are cases of false-negative
MRI findings as some glioblastoma lack the ringlike enhancement [6]. In discrim-
inating glioblastoma from grade III tumors, FDG PET is also not always adequate
as a large number of patients of grade III gliomas show high FDG uptakes [13, 14].
This makes a biopsy necessary in many cases, and a noninvasive in vivo
imaging tool would be of benefit to omit invasive biopsy procedures in clinical
settings [11].
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The WHO 2007 criteria determine the glioma grade based on microscopic
characteristics present in the malignancy. Grade II tumors show cell atypia and
grade III tumors tissue anaplasia and cell mitosis in addition to cell atypia. Grade IV
glioblastomas have pathological features that are not found in grade III or lower-
grade gliomas, particularly microvascular proliferation and necrosis [3]. Basically,
necrosis is considered to be closely related to hypoxia as low oxygen concentrations
do not allow the energy metabolism to proceed as in unaffected tissue. In fact,
glioblastomas are known to be in a state of severe hypoxia possibly due to vascular
abnormalities and high oxygen demand, whereas the hypoxia of grade III or lower-
grade gliomas is less severe [16–19]. We hypothesized that imaging the hypoxia of
glioblastomas could be useful to distinguish glioblastomas from lower-grade
gliomas.
Measuring hypoxia in living tissue uses needle electrodes; however, this tech-
nique presents significant shortcomings. First, it is invasive to insert a needle into
deep layers of tissue in humans. Second, it requires considerable skill and the
reproducibility is not high. Third, needles may alter the tissue structure and so
influence the local oxygen partial pressure, and for these reasons needle electrodes
are not used in clinical practice. An alternative is presented by 18F-fluoromiso-
nidazole (FMISO) PET which is a widely used method for in vivo hypoxia imaging
[20–23]. Valk et al. first introduced the use of FMISO for glioma imaging in 1992
[24], and the usefulness of FMISO for glioma imaging has been extensively
investigated [25–32]. The FMISO is also known to accumulate in severe hypoxic
structures but not in mildly hypoxic structures, suggesting that FMISO would be
able to discriminate severe from mild hypoxia. This made us hypothesize that much
FMISO may accumulate in glioblastomas and only little in lower-grade gliomas. If
such a difference could be substantiated, hypoxia imaging using FMISO would
provide an avenue to discriminate glioblastomas from lower-grade gliomas. The
first paper of our project was to test the hypothesis [1]. We evaluated the diagnostic
usefulness of FMISO PET in terms of glioma grading in comparison with diagnosis
with FDG PET in patients suspected of having glioblastomas on MR images.
With FMISO there is a trade-off problem regarding uptake time (the interval
between the FMISO injection and the PET emission scanning). A longer uptake
time is theoretically desirable to image hypoxia with good lesion-to-background
signal ratios, but the longer time leads to lower signal-to-noise ratios due to
radiological decay of the F-18. Early reports by Grunbaum et al. [33] and
Thorwarth et al. [34] addressing this issue suggested a 4-h acquisition as suitable.
Despite this, most research adopted 2-h protocols [24, 25, 27–32], possibly because
a shorter protocol would be more generally acceptable in clinical settings. Based on
this, the second part of our project was to directly compare 2-h and 4-h images from
the same patients [2].
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18.2 Materials and Methods
The first of the studies reported here was conducted for the purpose of testing the
ability to discriminate between glioblastomas and lower-grade gliomas with
FMISO PET. Twenty-seven patients with possible high-grade gliomas were con-
sidered for the study [1]. The patients included showed cerebral parenchymal
tumors surrounded by edematous tissue on MR images but no known malignancy
in other organs. We excluded patients where previous tumorectomy, chemotherapy,
or radiotherapy for lesions had been performed. The only exception was a patient
with a recurrent tumor 6 years after tumorectomy combined with
chemoradiotherapy for a low-grade glioma. Among the 27 patients, two were
excluded because they had contraindications of surgical operations. The remaining
25 patients underwent either a tumoral resection (n¼ 16) or biopsy (n¼ 9) at most
2 weeks after the PET scanning. The surgical specimen was investigated by two
experienced neuropathologists to determine the pathological diagnosis based on the
2007 WHO classification. Among the 25 patients, two were diagnosed as having
metastatic adenocarcinoma and multiple sclerosis, respectively, and these two
patients were excluded from the analysis. Finally 23 patients (M/F¼ 10:13, age
57 15 years old) all with the pathological diagnosis of gliomas were included in
the study.
With these 23 patients, we acquired FMISO and FDG PET images following the
same protocol for all the patients. The interval between FMISO and FDG was at
most 1 week. The FMISO synthesis protocol was previously described in detail
elsewhere [35, 36]. On the day of FMISO, the patient was not asked to fast before
the PET, and 400 MBq of FMISO was intravenously injected. Then, 4 h later, the
emission scanning was initiated to acquire static PET images of the entire brain.
FDG PET was performed on another day; here the dosage of FDG was also
400 MBq. The uptake time for FDG was 1 h, and the scanning range for the FDG
PET was the same for the FMISO PET with a high-resolution PET scanner (ECAT
HR+ scanner; Asahi-Siemens Medical Technologies Ltd., Tokyo, Japan) operated
in a three-dimensional mode for 22 patients. For one patient the FMISO images
were acquired using an integrated PET-CT scanner (Biograph 64 PET-CT scanner;
Asahi-Siemens Medical Technologies Ltd., Tokyo, Japan). The duration of the
emission scanning using the ECAT HR+ scanner was 10 min. The duration of the
transmission scanning using the ECAT HR+ scanner with a 68Ge/68Ga retractable
line source was 3 min. This acquisition protocol was the same for both FDG and
FMISO. With the Biograph 64 PET-CT scanner, the duration of the emission
scanning was also 10 min. The transmission scanning was performed using an X-
ray CT, and the attenuation correction used the CT images. The attenuation-
corrected radioactivity images from both scanners were reconstructed using a
filtered back projection with a 4 mm full width at half maximum Hann filter.
For our second study, to compare the 2-h vs. 4-h images of FMISO PET, we
investigated 17 different patients with brain tumors (M/F¼ 7:10, age 62 14 years
old, range 33–85 years old). The study populations for first and second studies were
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different, and none of the patients included in the first study were included in the
second study. The PET images for each patient in the second study were acquired
twice, 2 and 4 h following the injection. The injected dosage of FMISO was
399 25 MBq. The first scanning took place 115.9 14.6 min after the injection
and the second 227.4 15.1 min after injection. The scanner was a Gemini GXL 16
PET-CT (Philips). The duration of the emission scanning was 20 min. Transmission
scanning was performed using the X-ray CT which was used for attenuation
correction. Attenuation-corrected radioactivity images were reconstructed using
ordered subset expectation maximization.
For the first study, the images were analyzed both qualitatively and quantita-
tively. An experienced nuclear physician who was blinded from the pathological
diagnosis visually evaluated all the images in the qualitative assessment for the first
study. In the qualitative assessment of the FMISO PET images, the FMISO uptake
was visually categorized into three groups. Where the highest uptake in the tumor
was weaker than that in the surrounding brain tissue, the patient was considered as
showing low FMISO uptake. Where the highest uptake in the tumor was equal to
that in the surrounding brain tissue, the patient was considered as showing inter-
mediate FMISO uptake. Where the highest uptake in the tumor was stronger than
that in the surrounding brain tissue, the patient was considered as showing high
FMISO uptake. This grouping rule was however not efficient as no patients were
assigned to show low FMISO uptake. As a result the low FMISO uptake and the
intermediate FMISO uptake patients were combined in one group of FMISO-
negative patients. The remaining patients, those assigned to the high FMISO uptake
group, were designated as FMISO-positive patients. This binary division was
presented in a previous paper [27]. Similarly, in the qualitative assessment of the
FDG PET images, we evaluated the FDG accumulation in the tumor using the
grouping detailed elsewhere [14]. First, the FDG uptake was visually categorized
into three groups: low, intermediate, and high. Where the highest uptake in the
tumor was weaker than or equal to that in the contralateral white matter, the patient
was considered as showing low FDG uptake. Where the highest uptake in the tumor
was stronger than that in the contralateral white matter but weaker than that in the
contralateral gray matter, the patient was considered as showing intermediate FDG
uptake. Where the highest uptake in the tumor was equal to or stronger than that in
the contralateral gray matter, the patient was considered as showing high FDG
uptake. Like the FMISO categorization, the low FDG uptake and intermediate FDG
uptake patients were combined and termed FDG-negative patients, and those of
high FDG uptake were termed FDG-positive patients.
For the second study, the grouping of the FMISO uptake in the tumor was
performed slightly differently, here it was visually assessed. The degree of uptake
was assigned as either high, medium, or low. Low uptake here means the uptake
compared to the surrounding brain tissue.
Such qualitative assessments may be subjective and a quantitative assessment
was also made. For the first study, the PET images were coregistered with individ-
ual MR images (FLAIR) using a mutual information technique implemented in the
NEUROSTAT software package [37, 38]. Then, polygonal regions of interest
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(ROI) were manually drawn to enclose the entire tumor on every slice that also
included peritumoral edematous regions. The single voxel having the highest
radioactivity concentration in the tumor was determined in the PET images using
in-house software. The highest radioactivity concentration was used to calculate a
maximum standardized uptake value (SUVmax). A SUVpeak value has recently
come into use to overcome the shortcomings of SUVmax. However, the concept
of SUVpeak is not unique as different researchers use different definitions. Here, we
use the term SUV10mm to explicitly show the meaning: a 10-mm-diameter circular
ROI with the center at the maximum voxel was created. The averaged value for the
circular ROI was assigned as SUV10mm, and the SUV was calculated as (tissue
radioactivity [Bq/ml])*(body weight [g])/(injected radioactivity [Bq]). Next, fur-
ther ROIs were created on the following reference regions: the cerebellar cortex, the
contralateral frontoparietal cortex on the level of the centrum semiovale, and the
contralateral frontoparietal white matter on the level of the centrum semiovale. The
lesion-to-cerebellum ratio of the FMISO was determined as the ratio of the
SUV10mm to the cerebellar averaged SUV. The lesion-to-gray matter and lesion-
to-white matter ratios of the FDG were the ratios of SUV10mm to gray matter and
white matter SUV, respectively [13]. The ROI placement process was performed by
an experienced nuclear physician, and where the tumor occupied bilateral lobes, the
hemisphere with the larger part of the tumor was considered as the tumor side. We
further measured the hypoxic tissue volume showing significant FMISO uptake in
the tumor with the cerebellum used as the reference tissue for this purpose. The
voxels having higher SUV than 1.3 times that of the cerebellar SUV were extracted
in the tumoral polygonal ROI described above. No threshold for FMISO uptake
volumes has been established, and the 1.3 value was empirically adopted from
image segmentation in 11C-methionine brain PET [31, 39, 40]. The FMISO uptake
volumes were expressed as a percentage of the extracted voxels in the whole
tumoral ROI.
For the second study, the 2-h and 4-h images were coregistered to CT. To obtain
reference values from normal tissue, circular 10-mm-diameter ROIs were defined
on gray matter, white matter, and the cerebellar cortex. The SUVmean, standard
deviation (SD), and coefficient of variation (CV) were measured within these ROIs.
To express tumor uptake values, the SUVmax and lesion-to-cerebellum ratios were
calculated in the same way as in the first study.
In the following, all parametric data are expressed as means SD. The patients
with grade III or with less malignant gliomas were grouped together as non-
glioblastoma patients to simplify the analysis. The relationship between the histo-
pathological diagnosis and the visual assessment results was examined using
Fisher’s exact test. The differences in age, tumor size, SUVs, lesion-to-normal
tissue ratios, and uptake volume for glioblastoma vs. non-glioblastoma patients
were examined using the Mann-Whitney U-test. The 2-h vs. 4-h values were
compared using paired t-tests; P-values smaller than 0.05 were considered statisti-
cally significant. The statistical analysis and figure drawing used R 2.14.0 and R
3.1.3 for Windows.
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18.3 Results
In the first study, 14 patients were diagnosed with glioblastomas and categorized as
grade IV in the WHO classification. Among the remaining nine patients, one had
anaplastic astrocytoma (grade III), one had anaplastic oligodendroglioma (grade
III), three had anaplastic oligoastrocytomas (grade III), one had diffuse astrocytoma
(grade II), one had oligodendroglioma (grade II), and two had oligoastrocytomas
(grade II). Necrosis was identified in all the glioblastoma patients, while none of the
non-glioblastoma patients showed necrosis within the tumor. The age of the
glioblastoma patients was 65.5 9.9 years, and the age of non-glioblastoma
patients was 43.7 12.2 years; the age difference was statistically significant
( p< 0.01). The tumor sizes were measured on FLAIR MR images and were not
significantly different for glioblastomas vs. non-glioblastomas (64.4 17.5 mm vs.
77.6 22.5 mm in diameter) ( p¼NS). Gadolinium enhancement was observed in
3/9 non-glioblastoma patients and in14/14 glioblastoma patients. By visual assess-
ment, all of the glioblastoma patients (14/14) were classified as FMISO positive and
all of the non-glioblastoma patients as FMISO negative. There was a significant
association by Fisher’s exact test between the histology (glioblastoma or non-
glioblastoma) and FMISO uptake (FMISO positive or FMISO negative)
( p< 0.001). This visual assessment of the FMISO PET images correctly discrim-
inated glioblastoma patients from non-glioblastoma patients with sensitivity, spec-
ificity, and accuracy of 100 %, 100 %, and 100 %, respectively. For the FDG PET
results, after excluding a diabetic patient with hyperglycemia at the time of the FDG
PET, all glioblastoma patients (13/13) were FDG positive and 3/9 non-glioblastoma
patients were FDG positive. This relationship reached statistical difference
( p< 0.01), but the diagnostic performance of the FDG PET was poorer than the
FMISO PET, with sensitivity, specificity, and accuracy being 100 %, 66 %, and
86 %, respectively. Figures 18.1, 18.2, 18.3, 18.4, and 18.5 show representative
cases.
In the quantitative assessment of the first study, the SUVmax of the FMISO was
3.09 0.62 (range, 2.22–4.31) in glioblastoma patients, significantly higher than in
non-glioblastoma patients (1.73 0.36; range, 1.36–2.39) ( p< 0.001). As detailed
above, we introduced the SUV10mm term to be able to minimize noise effects. The
SUV10mm of FMISO was similar to the SUVmax of FMISO, with the values being
3.00 0.61 (range, 2.15–4.18), significantly higher than in non-glioblastoma
patients (1.64 0.38; range, 1.29–2.35) ( p< 0.001). The lesion-to-cerebellum
ratio of the FMISO (the SUV10mm/cerebellar SUV) was higher in the glioblastoma
patients (2.74 0.60; range, 1.71–3.81) than in the non-glioblastoma patients
(1.22 0.06; range, 1.09–1.29) ( p< 0.001). The quantitative results of the FDG
PET were slightly different from those of the FMISO PET. Here the diabetic patient
was also excluded from the analyses of SUV and the lesion-to-normal tissue ratio of
the FDG PET. The SUVmax of the FDG was not significantly different for the
glioblastoma and non-glioblastoma patients (7.55 3.72; range, 4.34–16.38, vs.
8.21 6.04; range, 4.75–23.49) ( p¼ 0.95). Similarly, the SUV10mm of the
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FDG was not significantly different for the glioblastoma and non-glioblastoma
patients (7.41 3.63; range, 4.26–15.90, vs. 8.03 5.96; range, 4.64–23.12)
( p¼ 0.95). The lesion-to-gray matter ratio of the FDG (the SUV10mm/SUV in the
contralateral gray matter) was higher in the glioblastoma patients (1.46 0.75;
range, 0.91–3.79) than in the non-glioblastoma patients (1.07 0.62; range,
0.66–2.95, p< 0.05). The lesion-to-white matter ratio of the FDG (the SUV10mm/
SUV in the contralateral white matter) was not significantly different for the
glioblastoma (2.81 1.23; range, 1.87–6.44) and non-glioblastoma (2.66 1.60;
Fig. 18.1 A glioblastoma case. (a) The FLAIR image showed a high-signal tumor in the left
hemisphere. (b) The tumor was enhanced by gadolinium contrast material. (c) The FDG uptake in
the tumor was comparable to that of contralateral cerebral cortex. (d) The FMISO uptake was
higher in the tumor than in the surrounding brain tissue
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range, 1.71–6.51) ( p¼ 0.16) patients. Finally, the uptake volume of FMISO was
larger in the glioblastoma than in non-glioblastoma patients (27.18 10.46 %;
range, 14.02–46.67 %, vs. 6.07 2.50 %; range, 2.12–9.22 %), ( p< 0.001).
In the second study, the 2-h images and the 4-h images of FMISO PET were
directly compared for the same subjects. Figure 18.6 shows representative images
that do not show tumors. Visually, the SUV in the brain was higher at 2 h than at 4 h.
More specifically, the gray matter SUV was higher at 2 h than at 4 h, whereas the
white matter SUV was comparable in the images at 2 h and 4 h. Profile curves
Fig. 18.2 A glioblastoma case. (a) The FLAIR image showed a tumor in the left frontal lobe. (b)
The tumor showed a ringlike enhancement by gadolinium contrast material. (c) The FDG uptake
was observed in a part of the gadolinium-enhanced area. The FDG uptake was comparable to the
right cerebral cortex. (d) The FMISO PET showed a similar distribution of FMISO as FDG but
with stronger tumor-to-background contrast than FDG
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demonstrate these differences in Figure 18.6. At 2 h, the gray matter was distin-
guishable from the white matter, as the gray matter showed higher SUV than the
white matter while at 4 h; the curve was almost flat. Figure 18.7 shows scatter plots
of gray and white matter SUV at 2 h vs. 4 h. In all cases the gray matter SUV
decreased with time and all the points plot under the line of identity. White matter
SUV was not significantly different at 2 and 4 h. Figure 18.8 shows the CV of gray
and white matter, compared at 2 h and 4 h. The gray matter CV increased slightly
from 2 to 4 h (P¼ 0.0008), while the white matter CV was not significantly
different at 2 and 4 h.
Fig. 18.3 An anaplastic oligoastrocytoma case (grade III). (a) The FLAIR image showed a tumor
in the right frontal lobe. (b) A small part of the tumor is enhanced after treatment with gadolinium
contrast material (arrowhead). (c) The FDG uptake was observed in the enhanced part (arrow-
head). The FDG uptake was higher than that in the left cerebral cortex. (d) No FMISO accumu-
lated in the tumor
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In the visual assessment of the tumors, we first looked into grade IV tumors
because based on the first study we believed that the grade IV tumors would have a
hypoxic volume and thus should show FMISO uptake. At 2 h, six out of eight grade
IV patients showed high FMISO uptakes, and the remaining two patients showed
medium uptakes. At 4 h, however, eight out of eight (100 %) patients showed high
FMISO uptakes. Then, we looked into grade II and III tumors that we thought
would not have developed severe hypoxia and thus would not show FMISO uptake.
At 2 h, three out of four patients showed medium uptakes and the fourth patient
showed a low uptake. This was changed at 4 h where four out of four (100 %)
patients showed low uptakes. The results of the visual assessment can be
Fig. 18.4 An anaplastic oligodendroglioma case (grade III). (a) The FLAIR image showed a
tumor in the left frontal lobe. (b) A part of the tumor enhanced by gadolinium contrast material. (c)
The FDG uptake was observed even outside the enhancing area. The FDG uptake was much higher
than that in the right cerebral cortex. (d) No FMISO uptake was observed in the tumor
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summarized as those 4-h images provide more definitive information for discrim-
inating grade IV tumors from lower-grade tumors. The quantitative analysis further
supported this; in all the cases, the SUVmax and tumor-to-normal ratio increased
from 2 h to 4 h (Fig. 18.9). Here, lower-grade gliomas (grades II and III) showed
decreases in SUVmax and in the tumor-to-normal ratio from 2 h to 4 h (Fig. 18.10).
Fig. 18.5 An oligodendroglioma case (grade II). (a) The FLAIR image showed a tumor in the left
temporal lobe. (b) The tumor slightly enhanced by gadolinium contrast material. (c) The FDG
uptake was weaker than in the right cerebral cortex. (d) No FMISO uptake was observed in the
tumor
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Fig. 18.6 A brain slice FMISO PET image (a) 2 h after administration of FMISO and (b) after 4 h.
No tumor existed on these slices. (c) 2-h SUV profile corresponding to the horizontal line in (a).
The red arrows indicate gray matter, and the white arrows indicate white matter. (d) 4-h profile
corresponding to the horizontal line (b)
Fig. 18.7 SUV of (a) gray and (b) white matter at 2 h vs. 4 h
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Fig. 18.8 Plot of variation (CV) of (a) gray and (b) white matter at 2 h vs. 4 h
Fig. 18.9 All glioblastoma cases showed increases in both the (a) SUVmax and (b) tumor-to-
normal ratio from 2 h to 4 h
Fig. 18.10 All grade II to III cases showed decrease in (a) SUVmax, and 3/4 cases showed
decrease in (b) tumor-to-normal ratio from 2 h to 4 h
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18.4 Discussion
We have detailed two studies in this article. The results of the first indicated that
much FMISO accumulated in all the glioblastomas here but not in the lower-grade
gliomas. Different from this, FDG accumulated in both glioblastomas (100 %) and
in some lower-grade gliomas (33 %). This suggests that FMISO PET is superior to
FDG PET in a differential diagnosis. Visual analysis was confirmed by analyses of
the SUV, lesion-to-normal tissue ratio, and FMISO uptake volume. The results of
the second study indicated that FMISO PET 4 h after administration is superior to
the images after 2 h in differentiating glioblastomas from non-glioblastomas.
In the 2007 WHO definition, grade IV gliomas show microvascular proliferation
and necrosis as well as anaplasia and mitotic activity [3]; necrotic tissue is not
observed in grade III or lower-grade gliomas. In brain tumor specimens, necrotic
change is an important histopathological landmark that distinguishes glioblastomas
from lower-grade gliomas. In previous reports, the necrosis in glioblastoma is
considered to be associated with tissue hypoxia [16, 17]. The FMISO PET identi-
fication of hypoxia proceeds through several steps. Injected FMISO is first
transported by the blood flow and taken up by viable cells. Then, FMISO is
oxidized by intracellular oxygen if there is a sufficient amount of oxygen available
in a cell, and the oxidized FMISO is excreted from the cell. The FMISO is not
oxidized when there is insufficient oxygen available (hypoxic conditions) and the
FMISO is here retained in the cell [41]. Considering these mechanisms, we may
expect that FMISO accumulates in perinecrotic hypoxic tissue but not in the central
necrotic region. We observed that only little FMISO accumulates in non-glioblas-
toma patients. Some studies used needle electrodes to measure oxygen partial
pressures in human gliomas [18, 19, 42] and have suggested that both glioblastomas
and grade II and III gliomas are present under hypoxic conditions. Lower-grade
gliomas do not develop necrosis and may be expected to suffer from only a milder
degree of hypoxia than that of glioblastomas [18, 19]. FMISO accumulation
requires severe hypoxic conditions (pO2< 10 mmHg) [43, 44], and the results
here are consistent with this.
Cher et al. investigated FMISO uptake in various tumors and the correlation with
histological findings [27]. They reported that all grade IV tumors showed high
FMISO uptakes (they were FMISO positive as we define it here) and that all grade I
and II tumors showed FMISO uptakes comparable to the surrounding tissue (they
were FMISO negative as we define it). However, there was a slightly elevated
FMISO uptake in one of three grade III patients and low uptakes in the remaining
two grade III patients [27]. Our results in the first study are consistent with this
previous data, except for the grade III patients, as all of our grade III gliomas were
FMISO negative. Cher et al. used 2 h as the waiting time before conducting the
FMISO PET scanning, while the study here used 4 h. Many FMISO PET protocols
have used 2 h as the uptake time [24, 25, 27–32], while Thorwarth et al. questioned
the adequacy of 2 h for imaging of FMISO [34]. There, the kinetic analysis of
dynamic datasets of FMISO PET suggested that the hot spots at 2 h did not reflect
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actual hypoxia but rather showed a high initial influx of the FMISO due to increased
blood flow to the tumor. In our first study, no grade III patients showed high FMISO
uptakes, and we speculated that this was possibly because the relatively long uptake
time allowed the tracer to be excreted from the tissue without severe hypoxia. To
further elucidate this, we conducted the second study, to directly compare images at
2 and 4 h after FMISO injection in the same patients. At 4 h, the background gray
matter SUV was lower, and the presence of the tumor uptake was fully substanti-
ated: all the glioblastomas were FMISO positive, and all the non-glioblastomas
were FMISO negative. These results are consistent with the Thorwarth observations
[34].
Recent advances in molecular targeting therapies and image guided therapies are
remarkable, and it may be expected that in the near future the therapy of first choice
for glioblastomas will be chemo- or radiotherapy rather than surgery. In such cases,
new techniques like FMISO PET may help avoid a biopsy followed by a patholog-
ical investigation. Aged patients or patients with impaired performance status
would particularly benefit from such techniques.
The FDG PET reflects the histological aggressiveness of gliomas, and glioblas-
tomas commonly show the highest FDG uptake among gliomas [12–14]. In the first
study here, a high FDG uptake was unexceptionally observed in glioblastoma
patients. At the same time, however, three of nine non-glioblastoma patients also
showed high FDG uptakes. These findings are consistent with the previous data [13,
14], and the results indicate that FDG PET is useful for histological grading but
inconclusive when a differential diagnosis of glioblastomas from lower-grade
gliomas is at issue. This leads us to suggest that FMISO PET may play a more
important role when a tumor shows a high FDG uptake (equal to or greater than the
uptake in the surrounding gray matter). Another important PET tracer for brain
tumor imaging is 11C-methionine (MET). For MET the uptake intensity
corresponding to each tumor grade can be summarized as in Fig. 18.11. It is well
Fig. 18.11 A scheme of the
suggested roles of 11C-
methionine (MET), 18F-
FDG, and 18F-FMISO PET
in differential diagnosis of
gliomas
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known that even grade II tumors may show high MET uptakes, especially in the
case of tumors with oligodendroglial components [45, 46], and that MET is good at
showing the tumor boundary. The FDG uptake increases with the tumor grade [47],
and the results here suggest that FMISO uptake is absent in grades II and III, but
strong in grade IV. Altogether these tracers will provide significant information to
assist in distinguishing tumor type and stage.
In the first study, the FMISO PET images were evaluated in different manners by
visual assessment, SUV, lesion-to-normal tissue ratio, and uptake volume. The
results of these analyses were consistent in showing the relationship between
FMISO uptake and glioma grade. In clinical settings the findings suggest that a
visual assessment is sufficient for a diagnosis, as the numerical values provide
information consistent with the visual assessment. The numerical values may
however be useful for purposes like assessing the prognosis and treatment response.
Both the SUVmax and SUV10mm with FMISO were higher in glioblastoma patients
than in non-glioblastoma patients; the range of the values for the groups overlaps,
possibly explained by inter-subject variability in the SUV. The lesion-to-cerebel-
lum ratio clearly distinguished glioblastoma patients from non-glioblastoma
patients. The usefulness of the lesion-to-cerebellum ratio has also been demon-
strated by Bruehlmeier et al. [26], by showing that lesion-to-cerebellum ratios were
comparable with the distribution of FMISO volumes. It may be argued that cerebral
glioma patients often show asymmetric blood flows in the cerebellum (the so-called
crossed cerebellar diaschisis) and that the cerebellar value may not be uniquely
useful as a reference. In the study here, FMISO accumulation of the left and right
cerebellar cortex did not show significant asymmetry (data not shown); however,
this may be assumed not to be a problem in using the lesion-to-cerebellum ratio.
To further confirm the findings, the uptake volume of FMISO in the tumor was
measured and compared for glioblastoma and non-glioblastoma patients. This
comparison showed that glioblastomas exhibited significantly larger uptake vol-
umes of FMISO than non-glioblastomas. In general, the hypoxic volume is distin-
guished with tissue-to-blood ratios 1.2 in images acquired 2 h after FMISO
injection with venous blood samples [28–31]. In brain tumor segmentation for
MET PET, a tumor-to-normal ratio 1.3 is frequently used [31, 39, 40, 48]. The
study here did not collect blood samples at the scanning but showed intratumoral
volumes in excess of a 1.3-fold cerebellum mean, which we consider an adequate
substitute. The method here did not directly quantify the hypoxic volume, and this
is one of the limitations of the study. As another limitation, the number of patients
included in this study is small, and further study with more patients is necessary to
substantiate the findings. In particular, such studies need to focus on small glio-
blastoma lesions and aggressive grade III tumors, because these could be a source
of false-negative or positive results. Third, we did not investigate specific immu-
nohistochemical features of hypoxia, like the hypoxia-inducible factor-1α (HIF-
1α). Investigating HIF-1α further reveals the oxygen condition in the tumor.
Finally, in clinical settings, metastatic brain tumors and malignant lymphomas
also require a diagnosis that will distinguish them from glioblastomas. Further,
additional and different types of brain tumors will need to be investigated.
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We also wish to briefly discuss PET tracers other than FMISO [23]. The slow
clearance of FMISO from tissue is a shortcoming in clinical settings. If the uptake
time could be shortened to maybe 1 h, this would improve the feasibility of hypoxia
imaging. Currently, FMISO is the tracer where most evidence has been accumu-
lated, but promising data have been published for other tracers as well. A review
article by Kurihara et al. on preclinical and clinical applications of hypoxia PET
tracers including FMISO also mentions 18F-fluoroerythronitroimidazole
(FETNIM), 18F-fluoroazomycin-arabinofuranoside (FAZA), and 62Cu or 64Cu-
diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) [49]. Among these,
FETNIM has not been used with brain tumors, while FAZA is less lipophilic than
FMISO, suggesting that background activity in the plasma could be excreted more
quickly than FMISO. This point is important for shortening the uptake time.
However, in an animal study, Sorger et al. have showed that faster clearance of
FAZA resulted in lower FAZA uptake in the tumor than with FMISO [50]. It is not
easy to solve this dilemma between uptake time and contrast. Postema et al.
conducted a study of FAZA PET in 50 patients with a number of different
malignant tumors, including seven glioblastoma patients [51]. Here images were
acquired 2–3 h after injection, and the image quality was reported as good, but not
superior to FMISO. With Cu-ATSM there is the advantage that the radionuclide
62Cu can be provided by a 62Zn/62Cu generator, which at present does not require an
on-site cyclotron to image hypoxia. O’Donoghue et al. conducted an animal study
using a R3327-AT tumor model and found a correlation between the 19-h images of
Cu-ATSM and FMISO images at 2–4 h as well as oxygen probe measurements [52].
However, 1-h images of Cu-ATSM did not correlate with the FMISO images. A
more recent study by Dence et al. compared Cu-ATSM with FMISO, FDG, and
18 F-fluorothymidine (FLT) using a 9 L gliosarcoma model. Here, autoradiography
showed a strong correlation between the Cu-ATSM and FMISO distributions [53].
Tateishi et al. acquired Cu-ATSM PET for glioma patients and demonstrated a
correlation between Cu-ATSM uptake and glioma grades [54]. Despite evidence, it
is still not substantiated whether Cu-ATSM represents hypoxia. Further, 18F-EF5,
2-(2-nitro-1[H]-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide, was
first tested in an animal study by Ziemer [55]. Evens et al. found that EF5 uptake
correlated with a poor prognosis in glioma patients [18]. They also reported
correlations of EF5 uptake with microscopic findings of vasculature [56] and
radiation responses [57].
18.5 Conclusions
This article summarizes our recent findings in two studies related to FMISO PET
for brain tumors. The first study demonstrated that much FMISO accumulated in
glioblastomas but not in lower-grade gliomas. The second study demonstrated that
FMISO PET images acquired 4 h after administration were better at showing
hypoxic tumors than the images acquired 2 h after injection. Combining these
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results, the 4-h FMISO PET may be useful in preoperatively discriminating glio-
blastomas from lower-grade gliomas.
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